1 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow XAV-19: new trials by email Literature Review of XAV-19 trials Research Report on XAV-19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19 XAV-19, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Xenothera SAS | 290 | 2021-04-28 | 2023-01-23 |
| Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia XAV-19, Placebo - SARS Virus | Phase 2 | Completed | Nantes University Hospital | 416 | 2020-09-01 | 2022-03-25 |
COVID-19 (2) · Lymphoma, Follicular (1) · Pneumonia (1) · Severe Acute Respiratory Syndrome (1)
Nantes University Hospital (1) · Xenothera SAS (1)
Bulgaria (1) · France (1) · Greece (1) · Martinique (1) · Reunion (1) · Romania (1) · Spain (1) · Turkey (Türkiye) (1)
Benjamin Gaborit (1)
PMID 33750432, PMID 34181475, PMID 34473343, PMID 36700518, PMID 38694503